Slide 1: Poised to Revolutionize the Carotid Intervention Market
Poised to Revolutionize the Carotid Intervention Market August 2026
Slide 2: Disclaimers
Disclaimers Forward-looking statements This presentation contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future f
Slide 3: Developer of CGuard Prime Carotid Stent Platform
Developer of CGuard® Prime Carotid Stent Platform Dedicated to advancing the prevention of stroke and treatment of carotid artery disease MicroNet Mesh-Covered Protection SmartFit Technology 3
Slide 4: Carotid Stenting Revolution Has Arrived
Carotid Stenting Revolution Has Arrived MicroNetTM covered CGuard® stent platform could become the new gold standard CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL ANEURYSMS ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE CAROTID ARTERY DISEASE 45%Endo 77% Endo2 65% Endo3 81% Endo4 70% Endo1 70% E
Slide 5: ~$1B U.S. Market Potential
~$1B U.S. Market Potential CAS/TCAR continues to gain over CEA US Market Size CEA CAS/TCAR $987M 30,000 $836M1 $296 25,000 $460 20,000 $277 15,000 CREST-2 $150 $207 10,000 CAS coverage publication expansion $113 TCAR coverage expansion $207 5,000 $113 2025 2030 - 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2
Slide 6: Carotid Stenting Procedure Volume is Underpenetrated
Carotid Stenting Procedure Volume is Underpenetrated Only ~10-15% of diagnosed patients treated annually ~160,000 ~1,000,000 Annual U.S. Procedures Untreated U.S. Diagnosed Patients 2025 35k 35k 90k Expanding Treatment Population CAS TCAR CEA • CMS coverage expansion broadens eligible treatment popu
Slide 7: Carotid Revascularization at an Inflection Point
Carotid Revascularization at an Inflection Point Momentum. Expansion. Acceleration. 2026 H1 2027 H2 2027 TAILWINDS SwitchGuard NPS for TCAR CMS Coverage Expanded Q2 2026 – CGUARDIANS III Trial Enhanced CGuard® Prime configuration Expands value capture across the full Standard Risk and Asymptomatic E
Slide 8: Long-Term Stent Performance is the Cornerstone of Our Business
Long-Term Stent Performance is the Cornerstone of Our Business Benefits are independent of access method We are positioned to CGuard Prime CAS Tandem capitalize on the ongoing Stroke Transfemoral/ paradigm shift toward a Transradial “stent first” approach and away from surgery CGuard® Prime Tandem T
Slide 9: A Picture is Worth a Thousand Words…
A Picture is Worth a Thousand Words… VS 90% occlusion CGuard® Stent Surgical Endarterectomy Stenting 9
Slide 10: Stent Design Comparison
Stent Design Comparison Conventional carotid stents vs CGuard® Prime dual layer design Conventional Carotid Stent CGuard Prime Dual Layer Design ▪ CGuard Prime is designed to prevent embolization by securing carotid plaque behind its MicroNet mesh, preventing prolapse through the stent struts while
Slide 11: Unmatched Foundational Data and Evidence
Unmatched Foundational Data and Evidence 11
Slide 12: The CGUARDIANS Family of Carotid Trials
The CGUARDIANS Family of Carotid Trials (InspireMD) C-GUARDIANS CGUARDIANS II CGUARDIANS III • CGuard® Prime 135cm w/commercially available EPDs (NAV6 and MOMA) • CGuard Prime 80cm w/ commercially • CGuard Prime 80cm w/ proprietary • 1-year primary endpoint results published available NPS (Enroute)
Slide 13: C-GUARDIANS: 30-Day Safety Outcomes
C-GUARDIANS: 30-Day Safety Outcomes 30-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 30-day outcomes 30-day DSMI (multiple FDA trials) Intention to Treat Per Protocol1,2 8.30% 30-day DSMI 0.95% (3) 0.63% (2) 5.80% 5.40% 5.20% 5.10% 4.80% Death 0.32% (1) 0.0% (0) 3.50%
Slide 14: C-GUARDIANS: 1 Year Outcomes
C-GUARDIANS: 1 Year Outcomes 365-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 365-day 365-day (multiple FDA trials) Intention to Treat Per Protocol1,2 12.20% 9.60% Primary Endpoint: 30-day 8.90% Death, Stroke, or MI + 1.93% (6) 1.70% (5) Ipsilateral Stroke between 7.
Slide 15: OUS Clinical Data Supporting CGuard Periprocedural Safety
OUS Clinical Data Supporting CGuard® Periprocedural Safety CGuard commercially available in Europe since 2015 (CE Mark) Study Year N DS 30-Day % (n) DSMI 30-Day % (n) CARENET 2015 30 0.0%(0) 0.0%(0) PARADIGM 2016 101 0.0%(0) 0.0%(0) CASANA 2017 82 1.22%(1) 1.22%(1) WISSGOTT I 2017 30 0.0%(0) 0.0%(0)
Slide 16: CARMEN Meta-Analysis (112 Studies, 68K Patients)
CARMEN Meta-Analysis (112 Studies, 68K Patients)1 30-day and 12-month event rates by stent type (random-effect model) Terumo Gore Event FGS SGS RoadSaver/ (not marketed) CGuard • Improvements from second- Casper generation stents (SGS) 30-day Stroke [%] 3.01 0.60 0.50 2.89 0.54 relative to first-gen
Slide 17: CREST-2 Outcomes Highlight CAS
CREST-2 Outcomes Highlight CAS • Stroke and death (S/D) out to 4-years Any Perioperative Stroke or Death Plus Ipsilateral Stroke Thereafter up to 4 Years was 6.0% for medical therapy and 2.8% when CAS was added • Absolute difference of 3.2% favoring CAS was significant Med Alone • Only 31 people wit
Slide 18: TCAR
TCAR INSPIREM9
Slide 19: CGUARDIANS II: Zero Major Adverse Events at 30 Days
CGUARDIANS II: Zero Major Adverse Events at 30 Days Preliminary results from first 36 TCAR patients | presented at Charing Cross Symposium 2026 30-DAY CLINICAL OUTCOMES (SECONDARY ENDPOINTS) Study Overview • Multicenter, single-arm pivotal U.S. trial evaluating CGuard® Prime (80cm) with TCAR using E
Slide 20: Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow
Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow InspireMD Combines SwitchGuard NPS with Best-in-Class CGuard® Implant 1. Transient flow reversal combined with sustained embolic prevention in transcervical revascularization of symptomatic and highly-emboligenic
Slide 21: Commercial and Corporate
Commercial and Corporate INSPIREM9
Slide 22: CMS Final National Coverage Determination, October 11, 2023
CMS Final National Coverage Determination, October 11, 2023 The final decision memorandum, which affects NCD 20.7 sections B4 and D, revises Medicare coverage for Percutaneous Transluminal Angioplasty (PTA) of the carotid arteries concurrent with stenting by: 1 Expanding coverage to individuals prev
Slide 23: Roadmap / Milestones
Roadmap / Milestones Key Value Drivers 2026 2027 ✓ CGUARDIANS II Enrollment Completion & PMA-S Submission CGuard Prime® indicated stent for TCAR Potential SwitchGuard NPS Clearance / Launch (Full TCAR Tool Kit) Potential CGuard Prime TCAR Approval CGuard Prime indicated stent with SwitchGaurd CGuard
Slide 24: Commercial Footprint
Commercial Footprint Current Markets • Active selling in more than 30 countries • Over 70,000 systems sold • Average CAS market share of 25% OUS 24
Slide 25: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued Pending USA 20 7 Rest of World 54 21 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products IP Counsel: Kligler and Associates, P.A
Slide 26: Transformational July 2025 PIPE and May 2023 Financing Up To $153.7 Million
Transformational July 2025 PIPE and May 2023 Financing Up To $153.7 Million To advance the company towards successful U.S. commercialization and path to profitability Strong validation from leading July 2025 PIPE Financing of $40.1 million fundamental healthcare investors, with additional participat
Slide 27: Scientific Advisory Board (Multidisciplinary KOLs)
Scientific Advisory Board (Multidisciplinary KOLs) Sean Lyden, M.D. Chris Metzger, M.D. Kenneth Rosenfield, M.D. Adnan H. Siddiqui, M.D., Ph.D. Vascular Surgeon Medical Director Interventional Cardiologist Professor, Vice Chairman of Cardiologist the Department of Neurosurgery 27
Slide 28: NASDAQ: NSPR
NASDAQ Nasdaq: =NSPR NSPR